264 related articles for article (PubMed ID: 16529882)
21. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
Severtson SG; Bartelson BB; Davis JM; Muñoz A; Schneider MF; Chilcoat H; Coplan PM; Surratt H; Dart RC
J Pain; 2013 Oct; 14(10):1122-30. PubMed ID: 23816949
[TBL] [Abstract][Full Text] [Related]
22. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004.
Cicero TJ; Inciardi JA; Adams EH; Geller A; Senay EC; Woody GE; Muñoz A
Pharmacoepidemiol Drug Saf; 2005 Dec; 14(12):851-9. PubMed ID: 15892169
[TBL] [Abstract][Full Text] [Related]
23. Involving the pharmaceutical and biotech communities in medication development for substance abuse.
Gorodetzky CW; Grudzinskas C
Pharmacol Ther; 2005 Oct; 108(1):109-18. PubMed ID: 16038981
[TBL] [Abstract][Full Text] [Related]
24. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
25. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
Webster L
Pain Med; 2009 Jul; 10 Suppl 2():S124-33. PubMed ID: 19691683
[TBL] [Abstract][Full Text] [Related]
26. Guiding principles of international and federal laws pertaining to medical use and diversion of controlled substances.
Joranson DE
NIDA Res Monogr; 1993; 131():18-34. PubMed ID: 8413529
[No Abstract] [Full Text] [Related]
27. Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2004 Sep; 69(188):58950-3. PubMed ID: 15455477
[TBL] [Abstract][Full Text] [Related]
28. Assessing abuse liability during drug development: changing standards and expectations.
Schoedel KA; Sellers EM
Clin Pharmacol Ther; 2008 Apr; 83(4):622-6. PubMed ID: 18212799
[TBL] [Abstract][Full Text] [Related]
29. Schedules of controlled substances: placement of Zopiclone into schedule IV. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2005 Apr; 70(63):16935-7. PubMed ID: 15806735
[TBL] [Abstract][Full Text] [Related]
30. Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2007 May; 72(85):24532-4. PubMed ID: 17520775
[TBL] [Abstract][Full Text] [Related]
31. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
32. When drugs in the same controlled substance schedule differ in real-world abuse, should they be differentiated in labeling?
Dasgupta N; Henningfield JE; Ertischek MD; Schnoll SH
Drug Alcohol Depend; 2011 Dec; 119(1-2):e1-4. PubMed ID: 21704462
[TBL] [Abstract][Full Text] [Related]
33. Control of immediate precursor used in the illicit manufacture of fentanyl as a schedule II controlled substance. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2010 Jun; 75(124):37295-9. PubMed ID: 20608285
[TBL] [Abstract][Full Text] [Related]
34. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2005 Jul; 70(144):43633-5. PubMed ID: 16050051
[TBL] [Abstract][Full Text] [Related]
35. Authority for practitioners to dispense or prescribe approved narcotic controlled substances for maintenance or detoxification treatment. Final rule.
Drug Enforcement Administration (DEA), Justice
Fed Regist; 2005 Jun; 70(120):36338-44. PubMed ID: 15973789
[TBL] [Abstract][Full Text] [Related]
36. Exempt chemical mixtures containing gamma-butyrolactone. Final rule.
Drug Enforcement Administration (DEA), Justice
Fed Regist; 2010 Jun; 75(124):37301-7. PubMed ID: 20608286
[TBL] [Abstract][Full Text] [Related]
37. The global political economy of scheduling: the international-historical context of the Controlled Substances Act.
McAllister WB
Drug Alcohol Depend; 2004 Oct; 76(1):3-8. PubMed ID: 15380283
[TBL] [Abstract][Full Text] [Related]
38. Designation of oripavine as a basic class of controlled substance. Final rule.
Drug Enforcement Administration (DEA), Justice
Fed Regist; 2007 Sep; 72(184):54208-10. PubMed ID: 17912784
[TBL] [Abstract][Full Text] [Related]
39. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs.
Schuster CR
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S8-14. PubMed ID: 16483729
[TBL] [Abstract][Full Text] [Related]
40. Schedules of controlled substances: placement of tapentadol into schedule II. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2009 May; 74(97):23790-3. PubMed ID: 19507329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
